TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06561087: Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 45 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06561087 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06561087 Rescue Dossier →